TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05742607: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Sponsor: Innate Pharma · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT05742607 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05742607 Rescue Dossier →